GeoVax Labs, Inc., a clinical-stage biotechnology company, announced it has entered into a warrant inducement agreement with existing healthcare-focused institutional investors. The agreement facilitates the immediate exercise of existing warrants to purchase up to 634,658 shares of the company's common stock at a reduced exercise price of $1.36. This transaction is expected to generate gross cash proceeds of approximately $863,000 before fees and expenses, with net proceeds intended for working capital and general corporate purposes.
In consideration for the immediate exercise of these existing warrants, the investor will receive new unregistered warrants in a private placement. These new warrants grant the right to purchase up to 1,269,316 shares of common stock, also at an exercise price of $1.36. The new warrants will become exercisable only after shareholder approval is obtained and will expire five years following that approval date. The closing of this transaction is anticipated around April 1, 2026, pending customary closing conditions.
The private placement of the new warrants and the underlying shares is being conducted under an exemption from registration, specifically relying on Section 4(a)(2) of the Securities Act of 1933 and Regulation D. Consequently, these securities cannot be offered or sold in the United States without an effective registration statement or an applicable exemption from registration requirements. This financial maneuver is designed to provide capital as GeoVax advances its pipeline.
The company's development priorities include GEO-MVA, a vaccine targeting mpox and smallpox that is on an expedited regulatory pathway with a pivotal Phase 3 trial planned for the second half of 2026. More information on the company's programs can be found at https://www.geovax.com. In oncology, GeoVax is developing Gedeptin, a gene-directed enzyme prodrug therapy intended to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 trial in advanced head and neck cancer. The broader pipeline also includes GEO-CM04S1, a next-generation COVID-19 vaccine candidate.
The capital raised through this warrant inducement transaction supports these ongoing research and development efforts aimed at addressing high-consequence infectious diseases and solid tumor cancers. This financing is critical for a clinical-stage company like GeoVax, as it provides non-dilutive capital in the near term while aligning investor incentives with long-term shareholder value through the new warrants. The structure demonstrates investor confidence in the company's pipeline and strategic direction. For public health, the advancement of GeoVax's programs could contribute to pandemic preparedness through its mpox/smallpox and COVID-19 vaccine candidates, while its oncology therapy addresses a significant unmet medical need in cancer treatment. The transaction's timing ahead of planned Phase 3 trials indicates strategic capital allocation to meet key clinical milestones.
